{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:11:02Z","timestamp":1792555862986,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":423,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with \u22656 months\u2019 follow-up was performed separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 103 patients initially included, 52 had a follow-up of at least 6 months (median follow-up of 303 days). At baseline, the mean age was 71.3 \u00b1 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%\u201339%) and 99% were taking beta-blockers, 96.1% sodium-glucose cotransporter-2 (SGLT2) inhibitors, 95.1% sacubitril\u2013valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P &amp;lt; 0.001), as did the EuroQol-5D (EQ-5D) and visual analogue scale (VAS) scores (from 0.83 \u00b1 0.13 to 0.87 \u00b1 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF-related hospitalizations\/decompensations within the previous 12 months was 2.3 \u00b1 1.4 and decreased with vericiguat to 0.79 \u00b1 1.14 (P &amp;lt; 0.001). At study end, 7.7% died (50% for HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15032","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T21:23:27Z","timestamp":1724016207000},"page":"4222-4230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-5850","authenticated-orcid":false,"given":"Mario","family":"Galv\u00e1n Ruiz","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Universidad de Las Palmas de Gran Canaria , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fern\u00e1ndez de Sanmamed Gir\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Val Groba Marco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Rojo Jorge","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pe\u00f1a Saavedra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mart\u00edn Bou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Andrade Guerra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Caballero Dorta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Garc\u00eda Quintana","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn , Las Palmas de Gran Canaria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"2026012113122131200_ehf215032-bib-0001","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/jcm11175199","article-title":"Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"11","author":"Escobar","year":"2022","journal-title":"J Clin Med"},{"key":"2026012113122131200_ehf215032-bib-0002","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: A report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2026012113122131200_ehf215032-bib-0003","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: Heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0004","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/imj.15253","article-title":"Temporal trends in the burden of heart failure","volume":"51","author":"Chan","year":"2021","journal-title":"Intern Med J"},{"key":"2026012113122131200_ehf215032-bib-0005","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.amjcard.2013.10.032","article-title":"Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study)","volume":"113","author":"Chang","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012113122131200_ehf215032-bib-0006","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113122131200_ehf215032-bib-0007","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ejhf.471","article-title":"The real-world evidence of heart failure: Findings from 41 413 patients of the ARNO database","volume":"18","author":"Maggioni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0008","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rec.2020.09.033","article-title":"Epidemiology and treatment of heart failure in Spain: The HF-PATHWAYS study","volume":"75","author":"Sicras-Mainar","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026012113122131200_ehf215032-bib-0009","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113122131200_ehf215032-bib-0010","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113122131200_ehf215032-bib-0011","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cardfail.2021.06.019","article-title":"Representativeness of the VICTORIA trial population in clinical practice: Analysis of the PINNACLE registry","volume":"27","author":"Butler","year":"2021","journal-title":"J Card Fail"},{"key":"2026012113122131200_ehf215032-bib-0012","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.cardfail.2022.04.015","article-title":"Epidemiology of worsening heart failure in a population-based cohort from Alberta, Canada: Evaluating eligibility for treatment with vericiguat","volume":"28","author":"Sepehrvand","year":"2022","journal-title":"J Card Fail"},{"key":"2026012113122131200_ehf215032-bib-0013","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/ehf2.13837","article-title":"Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction","volume":"9","author":"Oh","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0014","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-024-03654-0","article-title":"Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany","volume":"80","author":"Kerwagen","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012113122131200_ehf215032-bib-0015","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.3390\/jcm12134396","article-title":"Initial experience of vericiguat treatment in patients with heart failure and reduced ejection fraction","volume":"12","author":"Nakamura","year":"2023","journal-title":"J Clin Med"},{"key":"2026012113122131200_ehf215032-bib-0016","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14779072.2023.2215985","article-title":"What do Spanish registries report about worsening events in chronic heart failure? Needs and challenges","volume":"21","author":"Bonilla Palomas","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026012113122131200_ehf215032-bib-0017","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012113122131200_ehf215032-bib-0018","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-89289-0_2","volume-title":"Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide [Internet]","author":"Stolk","year":"2022"},{"key":"2026012113122131200_ehf215032-bib-0019","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40629-016-0006-7","article-title":"Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC)","volume":"26","author":"Klimek","year":"2017","journal-title":"Allergo J Int"},{"key":"2026012113122131200_ehf215032-bib-0020","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/03007995.2023.2189857","article-title":"Identifying the patient with heart failure to be treated with vericiguat","volume":"39","author":"Escobar Cervantes","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2026012113122131200_ehf215032-bib-0021","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jchf.2022.11.007","article-title":"Applicability of vericiguat to patients hospitalized for heart failure in the United States","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0022","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/ejhf.2939","article-title":"Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry","volume":"25","author":"Nguyen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0023","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","article-title":"Background medical therapy and clinical outcomes from the VICTORIA trial","volume":"16","author":"Ezekowitz","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0024","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: Insights from the VICTORIA trial","volume":"24","author":"Senni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0025","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0026","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0027","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial","volume":"10","author":"Lam","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012113122131200_ehf215032-bib-0028","doi-asserted-by":"publisher","first-page":"00840","DOI":"10.1016\/j.jchf.2023.12.005","article-title":"Recurrent hospitalizations and response to vericiguat in heart failure and reduced ejection fraction","volume":"S2213-1779","author":"Mentz","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0029","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to vericiguat according to index heart failure event: Insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113122131200_ehf215032-bib-0030","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, sex, and outcomes in heart failure with reduced EF: Insights from the VICTORIA trial","volume":"11","author":"Lam","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113122131200_ehf215032-bib-0031","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: Insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4222\/64516800\/eschf_11_6_4222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4222\/64516800\/eschf_11_6_4222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:26Z","timestamp":1769019266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/4222\/8269380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,18]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15032","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,18]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}